BMS-754807

Catalog No.S1124

Molecular Weight(MW): 461.49

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Cited by 6 Publications

Clin Cancer Res, 2013, 19(11):2984-94

PubMed: 23549869 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5866-77

PubMed: 25168481 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(7):1182-96

PubMed: ( click the link to review the publication )

Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Brain Res, 2018, 1678:407-418

PubMed: 29137974 ( click the link to review the publication )

PLoS One, 2015, 10(5):e0126867

PubMed: 25962155 ( click the link to review the publication )

1 Customer Review

Clin Cancer Res 2013 19(11), 2984-94. BMS-754807 purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Features

Muti-inhibitor of the IGR-1R/IR family.

Targets

Insulin Receptor ^[1] (Cell-free assay)	IGF-1R ^[1] (Cell-free assay)	TrkB ^[1] (Cell-free assay)	Met ^[1] (Cell-free assay)	TrkA ^[1] (Cell-free assay)	View More
1.7 nM	1.8 nM	4.1 nM	5.6 nM	7.4 nM	View More

In vitro

BMS-754807 effectively inhibits the growth of a broad range of human tumor cell lines of different histologic origins including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, and gastric), and hematopoietic (multiple myeloma and leukemia), the IC50 values range from 5 nM to 365 nM for the most sensitive cell lines. BMS-754807 inhibits proliferation of IGF-1R-Sal cells and RH41 cells with IC50 of 7 nM and 5 nM. BMS-754807 inhibits phosphorylation of IGF-1R in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 13 nM, 6 nM and 21 nM. BMS-754807 inhibits phosphorylation of Akt in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 22 nM, 13 nM and 16 nM. BMS-754807 induces greater apoptosis in Rh41 cells by 24 hours as indicated by an increased sub-G1 peak (23.1%), compared with control (2.4%). ^[1] BMS-754807 inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) in the IGF-Sal cell line with IC50 consistent with the antiproliferative IC50 (7 nM) in this cell line. The crystal structure of BMS-754807 cocrystallized with the kinase domain of IGF-1R shows that the donor/acceptor/donor hydrogen bond triad with Met1052 and Glu1050 within the hinge region of the kinase. ^[2] BMS-754807 shows a median EC50 value of 0.62 μM against 23 cell lines in the pediatric preclinical testing program (PPTP). ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Formulation	Activity Description	PMID
IGF-Sal	NIHqSIxMcW6jc3WgZZN{[Xl?			MmfQbY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCLR1[tNXIhMEmFNUCgQUAyO26PKTDhcoQhfGinIHTve45{fHKnYX2geIFz\2W2czDBb5QhMEmFNUCgQUAzOm6PKTDhcoQhVUGSSzCoTWM2OCB;IEGzcm0q	M{TSPFE6Pzd6MEK0
IGF-Sal	M135U2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7			NXj3W3E2UUN3ME23JI5O	M3nDPFE6Pzd6MEK0
CCRF-CEM (ALL)	MmS4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MoXSglUh\|ryP	NHj4e5NFVVOR	NXfwfY9GUUN3ME2xMlI{QSEQvF2=	MkXqNVk6QTZ{N{K=
PC3	MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NIjYeWt,PSEQvF2=	NHXHSo9FVVOR	NYP4VFhuUUN3ME2wMlk3PSEQvF2=	M4r5e\|E6QTl4Mkey
JD	M3\memdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Ml;3glUh\|ryP	MXzEUXNQ	M3\YNGlEPTB;MD6zPVEh\|ryP	MV[xPVk6PjJ5Mh?=
DU145	M4LSeGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MUj+OUDPxE1?	MoDHSG1UVw>?	NYfjXZpHUUN3ME2xMlQ3PSEQvF2=	NIXBOIsyQTl7NkK3Ni=>
KAG	M4X3Z2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M2DhNJ42KM7:TR?=	NGLBdY9FVVOR	MVjJR\|UxRTFwNk[1JO69VQ>?	MoHuNVk6QTZ{N{K=
K-562 (CML)	MUfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M1TpW542KM7:TR?=	Ml;aSG1UVw>?	MVrJR\|UxRTJwM{CyJO69VQ>?	MYSxPVk6PjJ5Mh?=
B6-P210 (Murine ALL)	MmTkS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NF7oVHd,PSEQvF2=	NWfBNFlRTE2VTx?=	MUXJR\|UxRTFwMkmzJO69VQ>?	MkjDNVk6QTZ{N{K=
LN CAP-FGC	Ml[wS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M2L4VJ42KM7:TR?=	MV3EUXNQ	MnPZTWM2OD1zLkSzOEDPxE1?	M3zBfFE6QTl4Mkey
VW	MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MXf+OUDPxE1?	MnXHSG1UVw>?	NHviPFJKSzVyPUCuNFE6KM7:TR?=	NYHSd5dDOTl7OU[yO\|I>
MV411 (B Myelomonocytic)	Ml;WS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M4TDXJ42KM7:TR?=	NUK3OIxoTE2VTx?=	M{Hje2lEPTB;MD6zN{DPxE1?	MUixPVk6PjJ5Mh?=
MDA-PCa-2b	NHX2[GVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NGj1cIF,PSEQvF2=	NF\we5JFVVOR	NXTLTFFrUUN3ME2wMlA6QCEQvF2=	NVfNWYNTOTl7OU[yO\|I>
LG	MoH4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NX;RflczhjVizszN	MnfqSG1UVw>?	MVjJR\|UxRTBwMEO4JO69VQ>?	MYGxPVk6PjJ5Mh?=
RS411 (B cell precursor-ALL)	MY\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NUfN[YpwhjVizszN	NWXLW4xXTE2VTx?=	Mly2TWM2OD1yLkGwNkDPxE1?	MnLaNVk6QTZ{N{K=
22-r-1	M3\hWWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MWL+OUDPxE1?	NWTkeXJPTE2VTx?=	NGDFR4ZKSzVyPUCuNVc2KM7:TR?=	MoS0NVk6QTZ{N{K=
5838	M1HR[Wdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFq5WYh,PSEQvF2=	MWXEUXNQ	NVvXZmpiUUN3ME2wMlA{PCEQvF2=	NFHibogyQTl7NkK3Ni=>
P388 (Murine)	MVLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MVj+OUDPxE1?	MXLEUXNQ	MYfJR\|UxRTRwMkeg{txO	NV7ufZJWOTl7OU[yO\|I>
A2780/S	M4XiTmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NUT0UFlqhjVizszN	MWrEUXNQ	M{L4fmlEPTB;MD6xNlIh\|ryP	NWS5fmpROTl7OU[yO\|I>
RDES	NX73O5ZPT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MX3+OUDPxE1?	MWjEUXNQ	NGDufVBKSzVyPUCuNFEzKM7:TR?=	M{fWNVE6QTl4Mkey
B6-T315I (Murine B-ALL)	MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXi2bpJOhjVizszN	MXPEUXNQ	NUXseGl3UUN3ME2yMlg{KM7:TR?=	NVrPPVI3OTl7OU[yO\|I>
TOV 112D	NEHGZYZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Mn3XglUh\|ryP	MkDySG1UVw>?	M{nhTGlEPTB;Mj6xOFYh\|ryP	NH65[2kyQTl7NkK3Ni=>
TC32	MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFH2[VN,PSEQvF2=	M1\hOWROW09?	NV;FUo83UUN3ME2wMlAxQCEQvF2=	MUKxPVk6PjJ5Mh?=
HL60 (acute myelocytic)	MnGzS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXz+OUDPxE1?	M1i4WGROW09?	MXjJR\|UxRTBwMUKg{txO	MVixPVk6PjJ5Mh?=
TOV 21G	NUS5N3luT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NFnidZV,PSEQvF2=	MYrEUXNQ	NH7H[5hKSzVyPUSuNlc6KM7:TR?=	Mn7pNVk6QTZ{N{K=
TC71	NX3STYdtT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NIG3epF,PSEQvF2=	NU\rSFRlTE2VTx?=	NHLLWHZKSzVyPUCuNFE1KM7:TR?=	NHq3N\|cyQTl7NkK3Ni=>
HPN-ALL (T-cell)	M2f2Omdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MXH+OUDPxE1?	M4f1eWROW09?	NYrve\|BbUUN3ME2wMlUzKM7:TR?=	MmPNNVk6QTZ{N{K=
A2780R	M13PcGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NF3rVI9,PSEQvF2=	MnzNSG1UVw>?	M1K0bGlEPTB;MT61OlQh\|ryP	MmjkNVk6QTZ{N{K=
Rh1	M17Fdmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFqyV2F,PSEQvF2=	NF;tdFhFVVOR	NH3IOolKSzVyPUCuNFI4KM7:TR?=	MlTJNVk6QTZ{N{K=
Kasumi-1 (acute myeloid)	NFf4[lZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NGHLU5d,PSEQvF2=	NHzKc\|lFVVOR	MlTKTWM2OD1yLkG2JO69VQ>?	MUGxPVk6PjJ5Mh?=
sk-ov-3	Mnu3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Mo\3glUh\|ryP	NH\5fIZFVVOR	NYPLWXhlUUN3ME21MlEh\|ryP	NXnZNWRNOTl7OU[yO\|I>
ME	MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnLtglUh\|ryP	MULEUXNQ	M{DNbmlEPTB;MD6wNVUh\|ryP	MX6xPVk6PjJ5Mh?=
L1210 (Murine lymphocytic)	NF[zdotIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmPZglUh\|ryP	MVHEUXNQ	NWi2T4t{UUN3ME2yMlM6KM7:TR?=	MXKxPVk6PjJ5Mh?=
sw-626	Ml72S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M1jlbZ42KM7:TR?=	NYL6V\|k3TE2VTx?=	MXjJR\|UxRTJwM{C2JO69VQ>?	Mn7FNVk6QTZ{N{K=
CTR	NWTRTGZxT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NI\mNXh,PSEQvF2=	MVPEUXNQ	NFXpVllKSzVyPUCuNlU{KM7:TR?=	NH35OZEyQTl7NkK3Ni=>
ML2 (Myelomonocytic)	MWHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M1HkT542KM7:TR?=	MlnpSG1UVw>?	Ml\2TWM2OD1yLkC5JO69VQ>?	NIXJXZMyQTl7NkK3Ni=>
ovcar-3	NGLtSWdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NHm1UlB,PSEQvF2=	NFPDfY1FVVOR	MVPJR\|UxRTVizszN	NGXtXY0yQTl7NkK3Ni=>
Rh36	NFPIdFBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MWT+OUDPxE1?	NV3tdmJ2TE2VTx?=	NGn2cpNKSzVyPUGuOFMzKM7:TR?=	NEDudFUyQTl7NkK3Ni=>
MOLM-13 (acute myeloid)	NVPXe4I3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M{nTUZ42KM7:TR?=	NX\KWmRJTE2VTx?=	MYjJR\|UxRTBwNEKg{txO	MkCwNVk6QTZ{N{K=
ovcar-4	M1jY[Wdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVP2bWI1hjVizszN	NWW5b3Y1TE2VTx?=	MoK1TWM2OD1zIN88US=>	M{LSS\|E6QTl4Mkey
Rh41	NVzEcJNRT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M2nxOZ42KM7:TR?=	NXXDU3QzTE2VTx?=	NIf3RZJKSzVyPUCuNFA2KM7:TR?=	Ml\GNVk6QTZ{N{K=
Mutz 2 (acute myeloid)	NVHRRZlST3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MUX+OUDPxE1?	NVLaeYhETE2VTx?=	Mo\JTWM2OD1zLkG1JO69VQ>?	MmrCNVk6QTZ{N{K=
ovcar-5	MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnXUglUh\|ryP	MYrEUXNQ	M3PYNWlEPTB;MD6wOUDPxE1?	NWDjR5RkOTl7OU[yO\|I>
RD1	NY\vXoZHT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnTBglUh\|ryP	M3X1UmROW09?	NXnR[XE2UUN3ME2wMlA3QCEQvF2=	M3qx[VE6QTl4Mkey
OCI-AML 2 (acute myeloid)	NWHjbm5lT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M{HqeZ42KM7:TR?=	MX3EUXNQ	NFTxNG1KSzVyPUOuN\|Mh\|ryP	NXfpZYNuOTl7OU[yO\|I>
786-O	NUHF[Zl7T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MX3+OUDPxE1?	NHXWdGdFVVOR	NVHW[pZTUUN3ME2xMlY1PyEQvF2=	Mlm1NVk6QTZ{N{K=
A673	NYLNRVAxT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NYfwfIJKhjVizszN	MXvEUXNQ	M4jXOmlEPTB;MD60NFgh\|ryP	MXuxPVk6PjJ5Mh?=
TALL-1 (T-cell)	M2XueWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MnLiglUh\|ryP	MnHwSG1UVw>?	MV\JR\|UxRTFwMkig{txO	NYDkfnJpOTl7OU[yO\|I>
151-B	M2TnWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFSybFd,PSEQvF2=	MnvOSG1UVw>?	NWPV[2hHUUN3ME2yMlY4KM7:TR?=	MkDuNVk6QTZ{N{K=
PFSK-1	NWX5OIVNT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MUX+OUDPxE1?	M3X6OWROW09?	NF7iVo5KSzVyPUCuNVMzKM7:TR?=	MYCxPVk6PjJ5Mh?=
THP-1	MkHuS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NGXCbIZ,PSEQvF2=	M3zKV2ROW09?	NGDMPJpKSzVyPU[uOVgh\|ryP	MoD4NVk6QTZ{N{K=
HEK293	MXXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NV3KVGdohjVizszN	MUXEUXNQ	NWq3S4JrUUN3ME2wMlkyPSEQvF2=	NHGwT3kyQTl7NkK3Ni=>
DAOY	MkG3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NVXKPVVZhjVizszN	NITibXBFVVOR	NHq4emNKSzVyPUGuPVc6KM7:TR?=	NYXScFVSOTl7OU[yO\|I>
SET2	NHj1UJJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NYX4VnR2hjVizszN	NF3Y[\|JFVVOR	MVnJR\|UxRTBwMkm4JO69VQ>?	Ml2yNVk6QTZ{N{K=
HTB-46	NEjQ[4lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MXz+OUDPxE1?	M4fDPWROW09?	MWjJR\|UxRTVwMkWg{txO	MYSxPVk6PjJ5Mh?=
SK-NAS	MYXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MUf+OUDPxE1?	Mnz2SG1UVw>?	M4Htc2lEPTB;MD60PVch\|ryP	NUK0fZhNOTl7OU[yO\|I>
CTLL2	MXXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M17EVp42KM7:TR?=	MnW3SG1UVw>?	MXnJR\|UxRjFwMECg{txO	NGOyS3kyQTl7NkK3Ni=>
HTB-47	MUPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVi2XWRWhjVizszN	Ml:4SG1UVw>?	NUXQ[Xo{UUN3ME2yMlA2PiEQvF2=	M1GxXFE6QTl4Mkey
LAN-1	MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MVT+OUDPxE1?	NIjvOnFFVVOR	NEfTc\|VKSzVyPUCuNFQh\|ryP	MlL6NVk6QTZ{N{K=
ST486	MmTWS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NH3XVop,PSEQvF2=	NFrDWZpFVVOR	M3\KRWlEPTB;MT6xPUDPxE1?	NGrXXGsyQTl7NkK3Ni=>
HS766T	Mk[0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3PET542KM7:TR?=	NYnO[IgyTE2VTx?=	NF\rUGNKSzVyPUKuNFAyKM7:TR?=	M{fFc\|E6QTl4Mkey
IMR-32	MnL2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MkH5glUh\|ryP	NHPTe5lFVVOR	M{XFfWlEPTB;MD6yOlEh\|ryP	M4jWNVE6QTl4Mkey
Daudi (Burkitt's)	NFzzUYZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NF;XOpN,PSEQvF2=	NH3pRXlFVVOR	NUDuVXg3UUN3ME2yMlY{PyEQvF2=	MojONVk6QTZ{N{K=
Aspc-1	NH\iTllIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Ml\0glUh\|ryP	MUHEUXNQ	NHWwOWZKSzVyPUCuN\|c6KM7:TR?=	M4fq[VE6QTl4Mkey
SK-NSH	NEfWTJpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3PIOp42KM7:TR?=	MkPiSG1UVw>?	NGTDOJBKSzVyPUCuNVM6KM7:TR?=	MVqxPVk6PjJ5Mh?=
MEC-1 (Chronic B cell)	M3\Ucmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVHwbJljhjVizszN	MVfEUXNQ	NWrDUo1pUUN3ME2yMlY{PyEQvF2=	M{jHPVE6QTl4Mkey
Capan-2	MlTtS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFfCeVd,PSEQvF2=	MkiwSG1UVw>?	M3:0PGlEPTB;MT63O\|Qh\|ryP	MlPwNVk6QTZ{N{K=
SHSY5Y	NIrSd41Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NWj4O5prhjVizszN	M1u0NGROW09?	NXjwbmNsUUN3ME2wMlExPiEQvF2=	NV34TItVOTl7OU[yO\|I>
U937 (Histioocytic)	NITlbZZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MoH0glUh\|ryP	MV7EUXNQ	MXPJR\|UxRjVwMECg{txO	MVqxPVk6PjJ5Mh?=
Bxpc-1	NUT6UFd4T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NIriZpV,PSEQvF2=	MWHEUXNQ	MUHJR\|UxRTFwOUK0JO69VQ>?	M2fhN\|E6QTl4Mkey
Bxpc-3	MWnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MkfpglUh\|ryP	MYDEUXNQ	MXzJR\|UxRjVwMECg{txO	MmrxNVk6QTZ{N{K=
HTB-92	MXTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnrDglUh\|ryP	M2PSbGROW09?	NHHufYlKSzVyPUGuNFIh\|ryP	MYOxPVk6PjJ5Mh?=
OCI-LY10 (B-cell)	NILH[GFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NEPyUm9,PSEQvF2=	MVjEUXNQ	NHLLZ4hKSzVyPUCuOFUh\|ryP	Ml;CNVk6QTZ{N{K=
PANC-1	NWTrV\|NMT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NEfTRZR,PSEQvF2=	Mn7JSG1UVw>?	M3LEOWlEPTB-NT6wNEDPxE1?	NYj6VnVqOTl7OU[yO\|I>
To184.T	MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NIm2UVV,PSEQvF2=	M{e0Z2ROW09?	MVzJR\|UxRTBwNE[5JO69VQ>?	MlfYNVk6QTZ{N{K=
OCI-LY19 (B-cell)	MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MUH+OUDPxE1?	MYfEUXNQ	MVzJR\|UxRTBwNDFOwG0>	MYCxPVk6PjJ5Mh?=
PANC-1 BM	NHrIV21Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M{jNTp42KM7:TR?=	M3\xWWROW09?	NFrvR4xKSzVyPkWuNFAh\|ryP	M4XRRlE6QTl4Mkey
SA-4	NW\lVW1GT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NFjFNmJ,PSEQvF2=	MUfEUXNQ	MXjJR\|UxRTFwM{CxJO69VQ>?	MorqNVk6QTZ{N{K=
RPMI 8226	NIPSZnRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M4DvOp42KM7:TR?=	M1HDS2ROW09?	MUfJR\|UxRTFwMkmzJO69VQ>?	M2HxWVE6QTl4Mkey
HPAF-II	MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MYL+OUDPxE1?	MXrEUXNQ	M2Kw[mlEPTB;MD62OFQh\|ryP	MYWxPVk6PjJ5Mh?=
SHP-77	MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWXGWVdVhjVizszN	NVvZc3NLTE2VTx?=	NVy1NWtrUUN3ME2xMlg5QCEQvF2=	M2WxdlE6QTl4Mkey
U266 B1	MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NULaW2c2hjVizszN	MVjEUXNQ	MlnjTWM2OD1zLk[2PUDPxE1?	NHPhfIwyQTl7NkK3Ni=>
Hs700t	NUDTZmNqT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NGryRWt,PSEQvF2=	M4XVVWROW09?	NEHiOXNKSzVyPUCuNlMyKM7:TR?=	NV;wdIdXOTl7OU[yO\|I>
NCI-446	M2DaSmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1fYSZ42KM7:TR?=	NXnnOmMzTE2VTx?=	M3fEZWlEPTB;MT6xOVQh\|ryP	M1;ZVFE6QTl4Mkey
H929	M{DGNmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NHzZXFl,PSEQvF2=	MoHYSG1UVw>?	MnzJTWM2OD1yLkCxOEDPxE1?	NE\3PJIyQTl7NkK3Ni=>
PL45	M{nz[2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVn+OUDPxE1?	MVTEUXNQ	MV3JR\|UxRTJwMkW1JO69VQ>?	M1nMVFE6QTl4Mkey
NCI-H383	NHP0RWNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NV;OOYtwhjVizszN	NYXyUHp7TE2VTx?=	MmXkTWM2OD53LkCwJO69VQ>?	NEDWPWEyQTl7NkK3Ni=>
JJN3	NH\3UVJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1zQep42KM7:TR?=	NU[yRpVTTE2VTx?=	M2LHNGlEPTB;Mj60N\|Mh\|ryP	MoPRNVk6QTZ{N{K=
SU.86.86	MVPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MoGxglUh\|ryP	NWLCe2hXTE2VTx?=	MoHWTWM2OD1{Lk[3NkDPxE1?	M{XGZlE6QTl4Mkey
H1299	NH;NXYFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MXn+OUDPxE1?	MmDISG1UVw>?	NW[4bld5UUN3ME61MlAxKM7:TR?=	MoLlNVk6QTZ{N{K=
MDA-MB-468	NULyXJM3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NYTlOppwhjVizszN	M1vud2ROW09?	NFrNNolKSzVyPUCuOVA1KM7:TR?=	NY[2eVR1OTl7OU[yO\|I>
SW1990	MnjaS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NInoXoF,PSEQvF2=	MUfEUXNQ	M4S4XGlEPTB;MD64NlYh\|ryP	MX2xPVk6PjJ5Mh?=
Calu-6	MkDRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MmnhglUh\|ryP	MlzySG1UVw>?	M3O3OWlEPTB-NT6wNEDPxE1?	Mlv3NVk6QTZ{N{K=
MDA-MB-231	NHL6TJJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3nmS542KM7:TR?=	M2[zdGROW09?	NGe0R25KSzVyPUGuOlQ5KM7:TR?=	M1n4OFE6QTl4Mkey
SW-684	NFi5[npIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NW\oU4Q{hjVizszN	NWfUV3JiTE2VTx?=	NVXKXHJbUUN3ME61MlAxKM7:TR?=	NFz0bnoyQTl7NkK3Ni=>
H209	M2XDbmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M4ji[p42KM7:TR?=	NHnM[lZFVVOR	NW\GWnkxUUN3ME2xMlE6OyEQvF2=	M1j4RVE6QTl4Mkey
MDA-MB-231T	M{jNR2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MYP+OUDPxE1?	NXvnN2hZTE2VTx?=	M4PLOWlEPTB-NT6wNEDPxE1?	M4f1cFE6QTl4Mkey
HT1080/S	MlPMS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NHHGWpZ,PSEQvF2=	NGqyS4pFVVOR	MlfOTWM2OD1yLkWzNUDPxE1?	M4fDXFE6QTl4Mkey
H526 0.044	M3\6eWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NWna[ZJbhjVizszN	NU\DcJJtTE2VTx?=	NVXEdWEyUUN3ME2wMlA1PCEQvF2=	MWexPVk6PjJ5Mh?=
DU4475 2.431	NG\wOZVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2f1dZ42KM7:TR?=	M13zcGROW09?	Mk\hTWM2OD1{LkSzNUDPxE1?	M2DWfFE6QTl4Mkey
HCT116	NVHRXnpnT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MW\+OUDPxE1?	M{H6fWROW09?	MlfpTWM2OD1yLki1NkDPxE1?	M1T1SlE6QTl4Mkey
M109	NFT0WYhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MlLDglUh\|ryP	NUTkfHRXTE2VTx?=	Mm\wTWM2OD1zLkC1OUDPxE1?	NX;lbnFXOTl7OU[yO\|I>
BT549	M2[3Omdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MojTglUh\|ryP	NVPnb2ZKTE2VTx?=	NXjWenZoUUN3ME2xMlY1PSEQvF2=	NVn0cYJnOTl7OU[yO\|I>
HCT116/VM46	MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MW\+OUDPxE1?	NXnVdm5ETE2VTx?=	NILi[JZKSzVyPUGuO\|AzKM7:TR?=	MlfSNVk6QTZ{N{K=
H460	NWPJWnFIT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVj+OUDPxE1?	NHTtPXVFVVOR	M1vpWmlEPTB;MD63PVUh\|ryP	NUDVVYpEOTl7OU[yO\|I>
MCF-7	M{C3dGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NXjYU217hjVizszN	NXjEXXdoTE2VTx?=	NHjWfW1KSzVyPUCuNFE3KM7:TR?=	Mn\mNVk6QTZ{N{K=
GEO	M{nqdWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NWLQbW5uhjVizszN	NHKy[IVFVVOR	MV;JR\|UxRTBwM{W2JO69VQ>?	MkLDNVk6QTZ{N{K=
H441 0.646	NYDLVFR2T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnP1glUh\|ryP	MXLEUXNQ	M2fQdWlEPTB;MD62OFYh\|ryP	MYKxPVk6PjJ5Mh?=
MCF-7-807R	MljPS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWL+OUDPxE1?	Ml3DSG1UVw>?	NYr4OFhqUUN3ME2wMlQ6KM7:TR?=	MkmwNVk6QTZ{N{K=
Colo205	MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXLweVdrhjVizszN	M3HmN2ROW09?	MoDlTWM2OD1yLkGwOEDPxE1?	MXixPVk6PjJ5Mh?=
H292	M1y2TWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NUnKPYRPhjVizszN	M2e3R2ROW09?	Mk\yTWM2OD1yLke4PEDPxE1?	M1nW[lE6QTl4Mkey
BT474 (S)	NV;EOXR3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NWXQU\|JzhjVizszN	M2TnWmROW09?	M3nncGlEPTB;Mj60NFMh\|ryP	MUKxPVk6PjJ5Mh?=
HT-29	MmjZS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NHvlfIt,PSEQvF2=	NFPYTZdFVVOR	NH;FZYpKSzVyPUKuNVA{KM7:TR?=	NY\nRXNMOTl7OU[yO\|I>
A549	M{PBVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MnrTglUh\|ryP	NXH6PYRpTE2VTx?=	NYPlZWVIUUN3ME2wMlY4PSEQvF2=	MmnlNVk6QTZ{N{K=
BT474-M1	NInmSpdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NFPIeIp,PSEQvF2=	M3X2[WROW09?	NXLS[ZJrUUN3ME2yMlM3PSEQvF2=	NHPMXWYyQTl7NkK3Ni=>
SW480	MX3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NU\5V5NwhjVizszN	NGTFeGFFVVOR	NFzFR3FKSzVyPkWuNFAh\|ryP	Ml7tNVk6QTZ{N{K=
L2987	NWS1c5A3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MoXPglUh\|ryP	MlmzSG1UVw>?	MV\JR\|UxRTBwNESyJO69VQ>?	NFrjXW0yQTl7NkK3Ni=>
AU565	M2Pmemdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mln5glUh\|ryP	MVHEUXNQ	MmPTTWM2OD12Lkm3JO69VQ>?	NV\NfJQ2OTl7OU[yO\|I>
SW403	MkXtS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWT+OUDPxE1?	MmC0SG1UVw>?	MlrJTWM2OD1yLkKyJO69VQ>?	NWHlU2htOTl7OU[yO\|I>
H1437	MmrNS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Mm\lglUh\|ryP	NInMbZZFVVOR	NID1SGtKSzVyPUCuOVI{KM7:TR?=	NUTNWmtEOTl7OU[yO\|I>
BT-20	MlXwS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NV2zbHVJhjVizszN	NUfic2ZyTE2VTx?=	M3jCOGlEPTB;Mz61OlIh\|ryP	NECzVJoyQTl7NkK3Ni=>
Colo320HSR	NX3KcG5ZT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	Mk\kglUh\|ryP	Mnz2SG1UVw>?	MVTJR\|UxRTBwMEGxJO69VQ>?	M2T3c\|E6QTl4Mkey
H2087	Mn36S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MlvUglUh\|ryP	MkLhSG1UVw>?	MkTVTWM2OD5zLkCwJO69VQ>?	MkDINVk6QTZ{N{K=
HCC1419	M{ixVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NF3hVGZ,PSEQvF2=	NGL5bo1FVVOR	NHzPNZZKSzVyPUKuOVE4KM7:TR?=	NGfRe28yQTl7NkK3Ni=>
WiDr	NILVPHhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Mm\LglUh\|ryP	M2fDbWROW09?	MmXSTWM2OD1yLkC3OkDPxE1?	M37lcVE6QTl4Mkey
H661 0.573	MnflS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NIXkUJV,PSEQvF2=	M{fyXmROW09?	M1vQZ2lEPTB;MD61O\|Mh\|ryP	NUPRbo9sOTl7OU[yO\|I>
HCC-38	NXv0bVk4T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NYfHSG1nhjVizszN	NYS5Z3o2TE2VTx?=	MXzJR\|UxRjVwMECg{txO	MmrJNVk6QTZ{N{K=
LS174T	NEmw[FVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NHzKVHh,PSEQvF2=	M{XLU2ROW09?	MXrJR\|UxRTBwNUO1JO69VQ>?	M37jfFE6QTl4Mkey
H211	MXrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MoSzglUh\|ryP	NFvQWmZFVVOR	NI\5S3BKSzVyPUCuO\|M{KM7:TR?=	MXyxPVk6PjJ5Mh?=
HCC70	NXXrSlNXT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MYr+OUDPxE1?	NIPlTmtFVVOR	MVrJR\|UxRTFwNUWg{txO	NXfBOYJ7OTl7OU[yO\|I>
SW116	NXvTc4xYT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4\rN542KM7:TR?=	MVnEUXNQ	M3HufGlEPTB;MD6wOlch\|ryP	NFzndmQyQTl7NkK3Ni=>
H513	M3LJeGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NIixeZN,PSEQvF2=	MUHEUXNQ	M2fqfGlEPTB;ND60OFgh\|ryP	NWnOfJhEOTl7OU[yO\|I>
MDA-MB-157	MorsS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MVj+OUDPxE1?	MVrEUXNQ	NFPNdo9KSzVyPUCuNFM3KM7:TR?=	NHP0OngyQTl7NkK3Ni=>
H2052	MVzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MXT+OUDPxE1?	MUDEUXNQ	NFT3SI1KSzVyPUGuNFUh\|ryP	MVWxPVk6PjJ5Mh?=
MDA-MB-415	MoPlS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MYX+OUDPxE1?	MV3EUXNQ	MoLRTWM2OD53LkCwJO69VQ>?	NFGxZoYyQTl7NkK3Ni=>
DLD-1	NIjJ[HVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NETQTXd,PSEQvF2=	M{PEUGROW09?	NYfYd3pMUUN3ME2wMlkxQSEQvF2=	MVOxPVk6PjJ5Mh?=
H2595	MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NF3WOHh,PSEQvF2=	NVHWflltTE2VTx?=	NGTtVXVKSzVyPUSuOFc2KM7:TR?=	MmnoNVk6QTZ{N{K=
MDA-MB-435S	NEjT[lZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NUO3c2xJhjVizszN	Mm\1SG1UVw>?	Mlv5TWM2OD1zLki2PUDPxE1?	M3r2Z\|E6QTl4Mkey
HCT15	MkfnS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NYWx[49yhjVizszN	Mnn6SG1UVw>?	MUXJR\|UxRjFwMECg{txO	NIPDc5gyQTl7NkK3Ni=>
SK-Hep1	NYfXbpZYT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M{T2cp42KM7:TR?=	NIXZOmRFVVOR	M1fae2lEPTB;MD6xOFYh\|ryP	MUSxPVk6PjJ5Mh?=
MDA-MB-436	NHzoT\|VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MXX+OUDPxE1?	MmD0SG1UVw>?	NHrWSIFKSzVyPUWuOVAzKM7:TR?=	MYexPVk6PjJ5Mh?=
KM12C	NGnmRmhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NFfkU4J,PSEQvF2=	MojPSG1UVw>?	Mn\5TWM2OD1yLkC1OEDPxE1?	MXSxPVk6PjJ5Mh?=
HEPG2	Mny4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M1\Kcp42KM7:TR?=	MnGzSG1UVw>?	NFK2NFFKSzVyPUCuNFI2KM7:TR?=	M4HMRVE6QTl4Mkey
MDA-MB-453	MYXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3fROp42KM7:TR?=	M4n5VWROW09?	NWS5fFhnUUN3ME2xMlg3QSEQvF2=	MV:xPVk6PjJ5Mh?=
KM12SM	MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWfCZotkhjVizszN	NW\yeJc4TE2VTx?=	M4rBXWlEPTB;MD6wOVkh\|ryP	MXKxPVk6PjJ5Mh?=
1483	MlflS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MlL5glUh\|ryP	MVTEUXNQ	MnG4TWM2OD1{LkG5JO69VQ>?	Mn2xNVk6QTZ{N{K=
Hs578t	NIPzbGFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NEKyWW5,PSEQvF2=	NGnNRZJFVVOR	NGHvPFZKSzVyPUGuNlg4KM7:TR?=	NXX1TGt6OTl7OU[yO\|I>
LS180	NHnxfldIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MWX+OUDPxE1?	M13oSmROW09?	MYjJR\|UxRTBwNkm2JO69VQ>?	M{PLd\|E6QTl4Mkey
FaDu	M2j2ZWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVXWRYxThjVizszN	Ml3ZSG1UVw>?	MlPDTWM2OD1zLkK3JO69VQ>?	NYnwWpBOOTl7OU[yO\|I>
ZR-75-1	MUnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mnz0glUh\|ryP	M{LNTmROW09?	NH\nWnRKSzVyPUKuNFg1KM7:TR?=	NYfON4loOTl7OU[yO\|I>
LS513	M{PFR2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NELHOIp,PSEQvF2=	NIiyRZpFVVOR	MWTJR\|UxRTBwMUO1JO69VQ>?	MXuxPVk6PjJ5Mh?=
Detroit.562	NV;hU\|d7T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NWTnPHhWhjVizszN	NIP5c2tFVVOR	MXfJR\|UxRTFwMUSg{txO	MX[xPVk6PjJ5Mh?=
ZR-75-30	MmDBS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MVT+OUDPxE1?	NWW0VnRmTE2VTx?=	MlHDTWM2OD53LkCwJO69VQ>?	NGnXPZkyQTl7NkK3Ni=>
RKO-PM	M4rZVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M3\nXZ42KM7:TR?=	MWTEUXNQ	NITjOotKSzVyPUCuNlMzKM7:TR?=	NFjJPHkyQTl7NkK3Ni=>
Cal.27	NHq2ZnBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NYDlUnBthjVizszN	MlTkSG1UVw>?	MYjJR\|UxRTJizszN	NV3VbZUzOTl7OU[yO\|I>
KPL4	NUGzUWt3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3zhZZ42KM7:TR?=	MmnXSG1UVw>?	MnqwTWM2OD1zLkK1NkDPxE1?	NEDRVHoyQTl7NkK3Ni=>
PKO-RM13	MXHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mm\mglUh\|ryP	M3f0VWROW09?	NWGxZXhMUUN3ME2wMlQzPSEQvF2=	NHTNNFIyQTl7NkK3Ni=>
HS.53.T	MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M2HiOZ42KM7:TR?=	MVHEUXNQ	NGjqS4NKSzVyPUCuO\|kh\|ryP	MXmxPVk6PjJ5Mh?=
EMT6	MYHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MU\+OUDPxE1?	NXnZdJBSTE2VTx?=	NF36O3NKSzVyPUCuPFA3KM7:TR?=	MVWxPVk6PjJ5Mh?=
SNU-C1	MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3znXJ42KM7:TR?=	NHrodWpFVVOR	NH;WNWFKSzVyPUCuNFA4KM7:TR?=	NW\ONXNkOTl7OU[yO\|I>
SQCCY1	M1PJdmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M4G4UZ42KM7:TR?=	MkfXSG1UVw>?	MmnuTWM2OD1yLke5JO69VQ>?	NXTzS4pUOTl7OU[yO\|I>
SW480	M3LpT2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MkXpglUh\|ryP	MmLZSG1UVw>?	NGHlcnNKSzVyPUCuNFM4KM7:TR?=	MV2xPVk6PjJ5Mh?=
SCC9	MoroS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NIfTe3Z,PSEQvF2=	M1PUb2ROW09?	NVnCc5hZUUN3ME2wMlc2KM7:TR?=	MnjTNVk6QTZ{N{K=
SK-LMS-1	M2rVdGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NILIcIZ,PSEQvF2=	MmfpSG1UVw>?	NHTqSoRKSzVyPUCuOlg4KM7:TR?=	MoWxNVk6QTZ{N{K=
SCC25	M4nVUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mm\CglUh\|ryP	Ml;tSG1UVw>?	NH3IOIZKSzVyPUCuOlgh\|ryP	MYGxPVk6PjJ5Mh?=
U87	MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MYX+OUDPxE1?	MX3EUXNQ	MoTOTWM2OD1yLkm1JO69VQ>?	NVnQXnQ1OTl7OU[yO\|I>
SCC15	MkSxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NXXO[Gw{hjVizszN	MYHEUXNQ	NGjqfVJKSzVyPUCuOlch\|ryP	NYrDRnZmOTl7OU[yO\|I>
T98G	M{fxZmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFHhTIN,PSEQvF2=	NV3ZXXoyTE2VTx?=	MVXJR\|UxRTFwMkG4JO69VQ>?	MoDtNVk6QTZ{N{K=
SCC4	MorDS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXT+OUDPxE1?	MXjEUXNQ	NHrud2ZKSzVyPUCuOlMh\|ryP	NXfISHFKOTl7OU[yO\|I>
U118	NV35fYh4T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MmPVglUh\|ryP	NWDjOoE4TE2VTx?=	M33tfmlEPTB;MT62NVgh\|ryP	MXyxPVk6PjJ5Mh?=
TU167	MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NIXoNYh,PSEQvF2=	Mn7qSG1UVw>?	NYnRVoNbUUN3ME20MlUzKM7:TR?=	MoPONVk6QTZ{N{K=
NCI-H727	NWLh[nBoT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4fLTp4yOOLCit88US=>	M37tZ2ROW09?	MWXJR\|UxRTR{ODDuUS=>	NWLIVY5[OjB\|OEW3OFc>
NCI-H720	MXXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NVzO[\|h4hjFy4pEK{txO	MnPFSG1UVw>?	NHfhXm9KSzVyPUKuPEDPxE1?	M1nDfFIxOzh3N{S3
NCI-H835	M3:wN2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M2DESp4yOOLCit88US=>	MojlSG1UVw>?	NYHWd\|V{UUN3ME2xJO69VQ>?	NV;HcIxsOjB\|OEW3OFc>
NCI-H727	M3zGS2tqdmG\|ZTDhd5NigQ>?	NYDHNJhShjFy4pEK{txO	NVjWcHlITE2VTx?=	MVnpcohq[mm2czDjc45{fGm2dYTpeoUhUUeIMWKgZZV1d3Cqb4PwbI9zgWyjdHnvci=>	NHLiboczODN6NUe0Oy=>
RD	NFLoSm9Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MkjlglEx6oDMzszN		MofhTWM2OD1zLkGyJOK2VQ>?	MVyyNVI6QDd2NR?=
Rh41	M2\6Wmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVvxW2VNhjFy4pEK{txO		M1y5WWlEPTB;MD6wO{DDvU1?	MUKyNVI6QDd2NR?=
Rh18	MmrCS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWn+NVDjiIsQvF2=		M{HDdWlEPTB;ND65OkDDvU1?	M1q4XFIyOjl6N{S1
Rh30	NVTtd5p4T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MX;+NVDjiIsQvF2=		M2Hod2lEPTB;MD6xPUDDvU1?	MWKyNVI6QDd2NR?=
BT-12	NX3uSGtiT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NITXfHp,OTEkgJtOwG0>		MmT4TWM2OD1yLke4JOK2VQ>?	M4e5eFIyOjl6N{S1
CHLA-266	NIXrNlNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M{HsU54yOOLCit88US=>		Mn;KTWM2OD1yLki5JOK2VQ>?	MY[yNVI6QDd2NR?=
TC-71	M{fvZWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M4jHR54yOOLCit88US=>		Mn[2TWM2OD1yLkGxJOK2VQ>?	MViyNVI6QDd2NR?=
CHLA-9	Mnn4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NHjnNWx,OTEkgJtOwG0>		NUXWUXhuUUN3ME2wMlEzKML3TR?=	M3L5eVIyOjl6N{S1
CHLA-10	M4n5dGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NEj3UIF,OTEkgJtOwG0>		NXvndpFsUUN3ME2wMlYzKML3TR?=	NXPQdoNUOjF{OUi3OFU>
CHLA-258	M4LDSWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVT+NVDjiIsQvF2=		MlXmTWM2OD1yLkK3JOK2VQ>?	NIPsS4wzOTJ7OEe0OS=>
GBM2	NVPMSZp[T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NE\oXol,OTEkgJtOwG0>		NHzOOI9KSzVyPUGuOFchyrWP	MUiyNVI6QDd2NR?=
NB-1643	NIK3dGtIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NE\JSZh,OTEkgJtOwG0>		MV7JR\|UxRTBwMUKgxtVO	M1zqdFIyOjl6N{S1
NB-EBc1	NVL6eVNYT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4j0Sp4yOOLCit88US=>		MoW4TWM2OD1yLkO1JOK2VQ>?	NXvyc29qOjF{OUi3OFU>
CHLA-90	MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M2XYS54yOOLCit88US=>		MkfFTWM2OD1yLke3JOK2VQ>?	M{PKfFIyOjl6N{S1
CHLA-136	M2izc2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NUfVSnE1hjFy4pEK{txO		NGnDVJZKSzVyPUCuOVIhyrWP	MnzmNlEzQTh5NEW=
NALM-6	M2LUcmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NXrJVZR4hjFy4pEK{txO		NWLOeVk{UUN3ME2wMlQ6KML3TR?=	NEXPOYUzOTJ7OEe0OS=>
COG-LL-317	Moq0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NGTzW2h,OTEkgJtOwG0>		NGTpPWxKSzVyPUGuN\|ghyrWP	MYGyNVI6QDd2NR?=
RS4;11	NYLtO5RZT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NWfoWFJohjFy4pEK{txO		MYXJR\|UxRTBwM{igxtVO	MUKyNVI6QDd2NR?=
MOLT-4	M3H4S2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NH\hbVl,OTEkgJtOwG0>		MX\JR\|UxRTBwNUOgxtVO	Mor4NlEzQTh5NEW=
CCRF-CEM	MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NGPXZZd,OTEkgJtOwG0>		M1TYcWlEPTB;MT6xN{DDvU1?	NXT4N3o1OjF{OUi3OFU>
Kasumi-1	MUHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFTjdW1,OTEkgJtOwG0>		NWTN[G1iUUN3ME2xMlIhyrWP	MoLQNlEzQTh5NEW=
Karpas-299	Ml;6S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M4DRdp4yOOLCit88US=>		MVjJR\|UxRTFwNkSgxtVO	MX[yNVI6QDd2NR?=
Ramos-RA1	MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFjrSYZ,OTEkgJtOwG0>		NFu4[ohKSzVyPUGuN\|EhyrWP	MXeyNVI6QDd2NR?=
Rh30	M2DtOmZ2dmO2aX;uJIF{e2G7			M2HZV4lv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?=	NIXl[pgzPTl{NUO3PC=>
Rh41	MmfXSpVv[3Srb36gZZN{[Xl?			M{LKUolv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?=	MUiyOVkzPTN5OB?=
RD	NGrWPZlHfW6ldHnvckBie3OjeR?=			NIm5S2dqdmS3Y3XzJIFvKGmwY4LlZZNmKG:oIGPGT{BxcG:\|cHjvdplt[XSrb36=	M1PKbFI2QTJ3M{e4
A549	M4fyNWtqdmG\|ZTDhd5NigQ>?	NITGWowxNjYkgJtOwG0>	MYjEUXNQ	M4fnbYlvcGmkaYTzJGlITi2LUj;JVkBi[3SrdnH0bY9v	NWXNNmZ6OjZ7Mki1O\|g>
NCI-H358	M2jpR2tqdmG\|ZTDhd5NigQ>?	M4rZO\|AvPeLCit88US=>	Mn;oSG1UVw>?	MVvpcohq[mm2czDJS2YuUVJxSWKgZYN1cX[jdHnvci=>	MVmyOlkzQDV5OB?=
A549	MULGeY5kfGmxbjDhd5NigQ>?	M3TxUVAvPeLCit88US=>	Mn:0SG1UVw>?	NHHOW2Vk[XW\|ZYOgZUBkd26ldYLy[Y51KGSnY4LlZZNmKGmwIIDoc5NxcG:{eXzheIVlKEGNVDDhcoQhTVKN	NEHISYkzPjl{OEW3PC=>
NCI-H358	NWS2b2NDTnWwY4Tpc44h[XO\|YYm=	NFTsZpkxNjYkgJtOwG0>	M2\iTGROW09?	MXnjZZV{\XNiYTDjc45kfXK{ZX70JIRm[3KnYYPlJIlvKHCqb4PwbI9zgWyjdHXkJGFMXCCjbnSgSXJM	MVSyOlkzQDV5OB?=
A549	NH7CeWVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2q5Wp4yOOLCit88US=>	MYDEUXNQ	MVzJR\|UxRTBwN{[g{txO	NUD0[lllOjZ7Mki1O\|g>
NCI-H358	MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MlLnglEx6oDMzszN	Mm\jSG1UVw>?	M2e4PGlEPTB;MT6wPUDPxE1?	MlP2NlY6Ojh3N{i=
A549	MmjPRZBweHSxc3nzJIF{e2G7	M4f5PVAvPeLCit88US=>	NELlO3dFVVOR	MXvpcoR2[2W\|IFHwc5B1d3Orcx?=	NYfEclU3OjZ7Mki1O\|g>
NCI-H358	M3:4[WFxd3C2b4Ppd{Bie3OjeR?=	M3TMOlAvPeLCit88US=>	NIPHc4tFVVOR	MV3pcoR2[2W\|IFHwc5B1d3Orcx?=	NXzFR\|ZkOjZ7Mki1O\|g>
A549	NVrYbJZPTnWwY4Tpc44h[XO\|YYm=	M1\zcVAvPeLCit88US=>	MVjEUXNQ	MlvXdoVlfWOnczD3c5Vv\CClbH;zeZJm	NHO5O\|kzPjl{OEW3PC=>
NCI-H358	M{iwV2Z2dmO2aX;uJIF{e2G7	M4fM[lAvPeLCit88US=>	MkPESG1UVw>?	MUfy[YR2[2W\|IIfveY5lKGOub4P1doU>	MX[yOlkzQDV5OB?=

... Click to View More Cell Line Experimental Data

In vivo

BMS-754807 (12.5mg/kg, orally) inhibits IGF-1R phosphorylation in tumor and serum in IGF-1R-Sal tumor–bearing nude mice. BMS-754807 inhibits tumor growth in a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with TGI ranging from 53% to 115%. ^[1] BMS-754807 (6.25 mg/kg) achieves complete tumor growth inhibition in the transgenic-derived IGF-Sal tumor mouse model with correlated inhibition of pIGF-1R and pAKT. The protein binding for BMS-754807 ranges from of 98.5% in mouse plasma to 95.9% in human plasma. BMS-754807 results in clearance of 113 (mL/min)/kg, 20 (mL/min)/kg, 3.5 (mL/min)/kg and 41 (mL/min)/kg. ^[2] BMS-754807 (25 mg/kg) significantly inhibits tumor in KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), and OS-1 xenografts mice model. ^[3]

Protocol

Kinase Assay:^[1]	+ Expand Kinase inhibition assays: The primary screen for BMS-754807 is an in vitro kinase assay using recombinant human IGF-1 receptor enzyme in biochemical assays using synthetic peptide KKSRGDYMTMQIG as a phosphoacceptor substrate. The selectivity profile is evaluated against multiple recombinant enzymes that are generated at BMS or purchased externally. The enzymatic assays are performed in Ubottom 384-well plates using a 30 μL reaction volume in assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl₂, 0.015% Brij35 and 4 mM DTT). The 60 minute reactions are initiated by combining ATP (concentration equivalent to K_m ATP), 1.5 μM fluoresceinlabeled peptide substrate, enzyme and BMS-754807. The reactions are terminated with EDTA. The reaction mixtures are analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data are calculated by comparison to enzyme-free control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Compounds are dissolved in dimethylsulfoxide (DMSO, 10mM stock) and evaluated at eleven concentrations. IC50 values are derived by non-linear regression analysis of the dose response curves.
Cell Research:^[1]	+ Expand Cell lines: IGF-1R-Sal, RH41 and Geo cell lines Concentrations: 365 nM Incubation Time: 72 hours Method: Cells are grown at their optimal density in RPMI +GlutaMax supplemented with 10% heat-inactivated fetal bovine serum (FBS), 10 mM Hepes, penicillin, and streptomycin. Cell proliferation is evaluated by incorporation of ³H-thymidine into DNA after exposure of cells to BMS-754807 for 72 hours. Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% compared with untreated control cells. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: IGF-1R-Sal, GEO, Colo205, JJN3, RD1 or Rh41 tumor–bearing nude mice Formulation: Mixture of polyethylene glycol 400 (PEG400/water (4:1; vol/vol) Dosages: 150 mg/kg Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	92 mg/mL (199.35 mM)
	Ethanol	92 mg/mL (199.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BMS-754807 SDF

Molecular Weight	461.49
Formula	C₂₃H₂₄FN₉O
CAS No.	1001350-96-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01525823	Completed	Healthy Volunteers	Bristol-Myers Squibb	February 2012	Phase 1
NCT01525823	Completed	Healthy Volunteers	Bristol-Myers Squibb	February 2012	Phase 1
NCT01225172	Completed	Breast Cancer	Bristol-Myers Squibb\|Mayo Clinic	December 2010	Phase 2
NCT01225172	Completed	Breast Cancer	Bristol-Myers Squibb\|Mayo Clinic	December 2010	Phase 2
NCT00908024	Terminated	Colorectal Cancer\|Head and Neck Cancer\|Neoplasm Metastasis	Bristol-Myers Squibb	October 2009	Phase 1\|Phase 2
NCT00908024	Terminated	Colorectal Cancer\|Head and Neck Cancer\|Neoplasm Metastasis	Bristol-Myers Squibb	October 2009	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Selective IGF-1R Inhibitor

NVP-AEW541 : IGF-1R-selective, IC50=86 nM.
IGF-1R Inhibitor in Clinical Trial

OSI-906 (Linsitinib) : Phase II for Advanced Solid Tumors.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.
Classic IGF-1R Inhibitor

BMS-536924 : ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

Related IGF-1R Products4

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R).
Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
R428 (BGB324|Bemcentinib) ^New

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
Linsitinib (OSI-906)

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
GSK1904529A

GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
AG-1024

AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

BMS-754807

Cited by 6 Publications

1 Customer Review

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BMS-754807 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products4

Choose Your Country or Region

By Signaling Pathways

By product type

BMS-754807

Cited by 6 Publications

1 Customer Review

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BMS-754807 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)